EyePoint Pharmaceuticals, Inc.

DB:PV3B Stock Report

Market Cap: €627.1m

EyePoint Pharmaceuticals Valuation

Is PV3B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PV3B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€25.08
Fair Value
64.8% undervalued intrinsic discount
12
Number of Analysts

Below Fair Value: PV3B (€8.83) is trading below our estimate of fair value (€25.08)

Significantly Below Fair Value: PV3B is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PV3B?

Key metric: As PV3B is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PV3B. This is calculated by dividing PV3B's market cap by their current revenue.
What is PV3B's PS Ratio?
PS Ratio14x
SalesUS$45.71m
Market CapUS$646.88m

Price to Sales Ratio vs Peers

How does PV3B's PS Ratio compare to its peers?

The above table shows the PS ratio for PV3B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.3x
PSG PharmaSGP Holding
2.8x7.3%€314.1m
DMP Dermapharm Holding
1.8x3.8%€2.2b
2FJ0 Pierrel
3.4xn/a€92.8m
0RX Redx Pharma
13.3x-37.6%€65.0m
PV3B EyePoint Pharmaceuticals
14x49.0%€646.9m

Price-To-Sales vs Peers: PV3B is expensive based on its Price-To-Sales Ratio (14x) compared to the peer average (5.3x).

Price to Sales Ratio vs Industry

How does PV3B's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

18 CompaniesPrice / SalesEstimated GrowthMarket Cap
PV3B 14.0xIndustry Avg. 3.0xNo. of Companies22PS048121620+
18 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: PV3B is expensive based on its Price-To-Sales Ratio (14x) compared to the European Pharmaceuticals industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is PV3B's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PV3B PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio14x
Fair PS Ratio3.3x

Price-To-Sales vs Fair Ratio: PV3B is expensive based on its Price-To-Sales Ratio (14x) compared to the estimated Fair Price-To-Sales Ratio (3.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PV3B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€8.83
€32.29
+265.9%
41.8%€65.72€17.40n/a12
Jan ’26€6.68
€32.28
+383.4%
43.6%€65.61€17.37n/a11
Dec ’25€8.57
€31.40
+266.5%
43.6%€63.82€16.89n/a11
Nov ’25€12.53
€33.39
+166.6%
36.3%€62.75€16.61n/a11
Oct ’25€7.17
€32.96
+359.5%
36.1%€61.18€13.50n/a11
Sep ’25€7.91
€32.96
+316.5%
36.1%€61.18€13.50n/a11
Aug ’25€9.09
€35.89
+294.7%
31.6%€63.48€26.14n/a9
Jul ’25€8.04
€35.89
+346.4%
31.6%€63.48€26.14n/a9
Jun ’25€9.69
€35.95
+271.0%
30.9%€63.04€25.96n/a9
May ’25n/a
€40.09
0%
23.8%€62.11€30.14n/a9
Apr ’25€18.90
€40.09
+112.1%
23.8%€62.11€30.14n/a9
Mar ’25€24.80
€40.04
+61.5%
25.5%€62.84€27.72n/a9
Feb ’25€24.80
€38.29
+54.4%
27.6%€62.49€27.57n/a9
Jan ’25€21.20
€39.71
+87.3%
27.4%€63.17€27.87€6.688
Dec ’24€5.65
€28.95
+412.5%
32.9%€51.79€18.83€8.578
Nov ’24€5.60
€29.34
+423.8%
32.3%€52.05€18.93€12.538
Oct ’24€7.50
€29.77
+296.9%
29.9%€50.27€20.11€7.177
Sep ’24€9.00
€29.77
+230.8%
29.9%€50.27€20.11€7.917
Aug ’24€11.20
€30.15
+169.2%
29.9%€50.91€20.36€9.097
Jul ’24€7.50
€30.15
+302.0%
29.9%€50.91€20.36€8.047
Jun ’24€5.60
€30.15
+438.4%
29.9%€50.91€20.36€9.697
May ’24€5.60
€29.58
+428.3%
28.2%€47.44€19.16n/a7
Apr ’24€2.08
€30.39
+1,360.9%
30.5%€48.87€19.74€18.906
Mar ’24€3.12
€30.12
+865.3%
30.5%€48.44€19.56€24.806
Feb ’24€4.22
€30.12
+613.7%
30.5%€48.44€19.56€24.806
Jan ’24€3.22
€31.21
+869.4%
30.5%€50.20€20.27€21.206
Analyst Price Target
Consensus Narrative from 12 Analysts
€32.37
Fair Value
72.7% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 13:52
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

EyePoint Pharmaceuticals, Inc. is covered by 20 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Andrew D'SilvaB. Riley Securities, Inc.
Jennifer KimCantor Fitzgerald & Co.